Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate.

Seifert, Karin; Juhls, Christiane; Salguero, Francisco J; Croft, Simon L

Seifert, Karin; Juhls, Christiane; Salguero, Francisco J; Croft, Simon L.

Affiliation

Seifert K; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom karin.seifert@lshtm.ac.uk.
Juhls C; Mologen AG, Berlin, Germany.
Salguero FJ; Animal Health and Veterinary Laboratories Agency, New Haw, Surrey, United Kingdom School of Veterinary Medicine, University of Surrey, Guildford, Surrey, United Kingdom.
Croft SL; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Antimicrob Agents Chemother ; 59(9): 5819-23, 2015 Sep.

Article in En | MEDLINE | ID: mdl-26055371

Subject(s)

Amphotericin B/therapeutic use; Antiprotozoal Agents/therapeutic use; Leishmaniasis, Visceral/drug therapy; Vaccines, DNA/therapeutic use; Animals; Female; Immunotherapy/methods; Mice; Mice, Inbred C57BL

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Amphotericin B / Vaccines, DNA / Leishmaniasis, Visceral / Antiprotozoal Agents Limits: Animals Language: En Journal: Antimicrob Agents Chemother Year: 2015 Type: Article Affiliation country: United kingdom

Fulltext

XML

PubMed Links

Search on Google